# Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

> **NCT02630966** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 34 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02630966
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-10
- **Primary completion:** 2018-09-04
- **Final completion:** 2018-11-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630966, "Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02630966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*